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a b s t r a c t
The degradation of human ether-a-go-go-related gene (hERG, KCNH2) transcripts containing premature termination codon (PTC) mutations by nonsense-mediated mRNA decay (NMD) is an important mechanism of long QT
syndrome type 2 (LQT2). The mechanisms governing the recognition of PTC-containing hERG transcripts as NMD
substrates have not been established. We used a minigene system to study two frameshift mutations,
R1032Gfs*25 and D1037Rfs*82. R1032Gfs*25 introduces a PTC in exon 14, whereas D1037Rfs*82 causes a PTC
in the last exon (exon 15). We showed that R1032Gfs*25, but not D1037Rfs*82, reduced the level of mutant
mRNA compared to the wild-type minigene in an NMD-dependent manner. The deletion of intron 14 prevented
degradation of R1032Gfs*25 mRNA indicating that a downstream intron is required for NMD. The recognition
and elimination of PTC-containing transcripts by NMD required that the mutation be positioned N54–60 nt upstream of the 3′-most exon–exon junction. Finally, we used a full-length hERG splicing-competent construct to
show that inhibition of downstream intron splicing by antisense morpholino oligonucleotides inhibited NMD
and rescued the functional expression of a third LQT2 mutation, Y1078*. The present study deﬁnes the positional
requirements for the susceptibility of LQT2 mutations to NMD and posits that the majority of reported LQT2 nonsense and frameshift mutations are potential targets of NMD.
© 2014 Elsevier B.V. All rights reserved.

1. Introduction
The long QT syndrome type 2 (LQT2) is caused by mutations in the
human ether-a-go-go-related gene (hERG, KCNH2) (Curran et al.,
1995). hERG encodes the pore forming subunit of the rapidly activating
delayed rectiﬁer K+ channel in the heart. Over ﬁve hundred mutations
have been identiﬁed in patients with LQT2 (Kapplinger et al., 2009;
Lieve et al., 2013; Nagaoka et al., 2008; Napolitano et al., 2005;
Splawski et al., 2000; Tester et al., 2005). More than 30% of LQT2
mutations are nonsense or frameshift mutations that introduce premature termination codons (PTCs). We previously reported that PTCcontaining hERG mRNAs are degraded by nonsense-mediated mRNA
decay (NMD) (Bhuiyan et al., 2008; Gong et al., 2007; Zarraga et al.,
2011). NMD is an RNA quality control mechanism that selectively
degrades mRNA harboring PTCs (Kuzmiak and Maquat, 2006). NMD
eliminates abnormal mRNA transcripts harboring PTCs, and thereby
Abbreviations: CHX, cycloheximide; EJC, exon junction complex; hERG, human ethera-go-go-related gene; HPH, hygromycin B phosphotransferase; LQT2, long QT syndrome
type 2; MO, morpholino oligonucleotide; NMD, nonsense-mediated mRNA decay; nt, nucleotide; PTC, premature termination codon; RPA, RNase protection assay; shRNA, short
hairpin RNA; UPF1, up-frameshift protein 1; WT, wild-type.
⁎ Corresponding author at: Knight Cardiovascular Institute, Oregon Health & Science
University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
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preventing the production of truncated proteins that often have
dominant-negative effects. Thus, NMD protects against severe disease
phenotypes by converting dominant-negative effects to haploinsufﬁciency (Khajavi et al., 2006).
The identiﬁcation of potential NMD targets has important implications in genotype–phenotype correlations in LQT2. The LQT2 mutation
R1014* generates truncated hERG channel protein that exhibits a
dominant-negative effect on the wild-type (WT) channel in the context
of the hERG cDNA construct (Gong et al., 2004). However, when an
intron-containing minigene is used, the R1014* mutant mRNA is
decreased by NMD (Gong et al., 2007). Therefore, haploinsufﬁciency
rather than dominant-negative effect is the underlying mechanism for
the R1014* mutation. Most mutation carriers in this family have a
mild clinical phenotype which is consistent with this mechanism
(Gong et al., 2007). In some cases, NMD could be detrimental if it prevents
the production of truncated proteins that are fully or partially functional.
This is typiﬁed in the LQT2 Q1070* mutation in which NMD results in a
nearly complete elimination of mutant mRNA, precluding the formation
of functional, truncated channels (Bhuiyan et al., 2008). Although several
LQT2 nonsense and frameshift mutations have been shown to induce
NMD, the mechanisms by which the NMD machinery recognizes PTCcontaining hERG transcripts have not been established.
There are currently several models that describe the recognition of
NMD substrates in mammalian cells. The classic model posits that

NMD occurs when translation terminates N50–55 nt upstream of the 3′most exon–exon junction (Kuzmiak and Maquat, 2006). According to
this model NMD is linked to splicing and translation. Pre-mRNA
splicing results in deposition of a multi-protein complex, known as
exon-junction-complex (EJC), 20–24 nt upstream of each exon–exon
junction (Kuzmiak and Maquat, 2006). The EJCs are displaced by the ribosome during the pioneer round of translation. If translation terminates at a PTC that is located 50–55 nt upstream of an exon–exon
junction the downstream EJC serves as a binding platform for NMD factors that trigger NMD. Recent studies, however, have challenged the
EJC-dependent model of NMD. For instance, PTCs located as close as
8–10 nt upstream of the 3′-most exon–exon junction still elicit NMD
in T cell receptor-β and Ig-μ transcripts (Bühler et al., 2006; Carter
et al., 1996). Insertion of an intron downstream of β-globin termination
codon does not elicit NMD, whereas some PTCs that are located in the
last exon or even in intron-less mRNA trigger NMD, suggesting that
the presence of a downstream intron is neither sufﬁcient nor required
for triggering NMD (Bateman et al., 2005; Bühler et al., 2006; Rajavel
and Neufeld, 2001; Singh et al., 2008). These experimental data support
an EJC-independent model in which the physical distance between the
termination codon and the poly(A)-binding protein C1 is a crucial determinant for recognition of NMD substrates (Eberle et al., 2008). Clearly, the mechanisms that deﬁne the susceptibility of PTC-containing
mRNA to NMD may vary in different genes. To understand the mechanisms by which the NMD machinery discriminates between premature
and normal termination codons in hERG it is necessary to determine the
positional requirements associated with NMD-sensitivity and NMDresistance. In this study we used hERG minigene and full-length hERG
splicing-competent constructs to investigate the role of LQT2 PTC position in susceptibility of LQT2 mutations to NMD.
2. Materials and methods

the N-terminus of the hERG channel protein (H175, Santa Cruz Biotechnology Inc., Santa Cruz, CA). The expression level of hygromycin B phosphotransferase (HPH) encoded by hygromycin B resistance gene in the
pcDNA5 vector was used as an internal control for normalization. The
polyclonal antibody against HPH was used at 1:1000 dilution as previously described (Gong et al., 2010).
2.3. RNA interference
An UPF1 short hairpin RNA (shRNA), targeting the coding sequence
of hUPF1 (5′-GAGAATCGCCTACTTCACT-3′), was used to inhibit expression of UPF1 (Gong et al., 2007). A double stable mammalian expression
system was used to express hERG minigenes and UPF1 shRNAs. The design of the Flp–Cre cell line has been previously described (Stump et al.,
2012a). Brieﬂy, a loxP2272/loxP target site was introduced into Flp-In
HEK293 cells (Invitrogen, Carlsbad, CA) at a single genomic locus. Flp
recombinase-mediated recombination and Cre recombinase-mediated
cassette exchange reactions were performed to stably introduce a single
copy of each gene of interest. The WT hERG and R1032Gfs*25 mutant
minigenes were introduced into the Flp–Cre HEK293 cells at the FRT
site, whereas the UPF1 and scramble shRNAs were introduced into the
Flp–Cre HEK293 cells at the loxP2272/loxP site. The knockdown of the
UPF1 protein was analyzed by immunoblot as previously described
(Gong et al., 2007).
2.4. Morpholino oligonucleotide treatment
Morpholino oligonucleotides (MO) were synthesized by Gene Tools
(Philomath, OR). The antisense MO (5′-AAGCAGGGCTGGAGCTTACCTG
AGA-3′) was designed to target the 5′-splice site of intron 14 (Gong
et al., 2011). An invert MO with the same sequence but in reverse orientation was used as control. The Endo–Porter method was used to deliver
MOs into the cells.

2.1. Plasmid constructs and transfection
2.5. Patch-clamp recordings
The hERG minigene spanning exons 12–15 and the full-length hERG
splicing-competent construct composed of hERG cDNA exons 1–10 and
hERG genomic DNA from intron 10 to poly(A) site were generated as
previously described (Gong et al., 2007, 2011). The full-length splicing
competent construct encodes the full-length hERG potassium channel
which corresponds to the hERGa isoform (NM_000238.3). The hERG
mutations were generated by pAlter mutagenesis system (Promega,
Madison, WI). Flp-In HEK293 cells (Invitrogen, Carlsbad, CA) were
stably transfected with pcDNA5 hERG minigenes or full-length
hERG splicing-competent constructs and selected with 100 μg/ml
hygromycin B. The Flp-In HEK293 cells contain the FRT site at a single
genomic locus, allowing stable integration of hERG constructs via Flp
recombinase-mediated DNA recombination at a speciﬁc genomic location
in all cell clones.
2.2. RNase protection assay and immunoblot analysis
RNase protection assay (RPA) was performed as previously described (Gong et al., 2011). Brieﬂy, antisense RNA riboprobes were transcribed in vitro in the presence of biotin-14-CTP. The probe contained
277 nt spanning the region of exons 12 and 13. The total length of the
probe was 409 nt and contained sequences from the pCRII vector at
both ends. The expression level of hygromycin B resistance gene in
the pcDNA5 vector was used as an internal control for normalization.
The probe for the hygromycin B resistance gene contained 158 nt of
the gene and 70 nt from the pGEM vector. Yeast RNA was used as a control for the complete digestion of the probes by RNase. The relative intensity of RPA bands was quantiﬁed using ImageJ.
Immunoblot was performed as previously described (Gong et al.,
2010). The cell lysates were subjected to SDS-polyacrylamide gel
electrophoresis and the blots were probed with an antibody against

Membrane currents were recorded in whole-cell conﬁguration as
previously described (Gong et al., 2004). The bath solution contained
(in mM) 137 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 glucose, and 10 HEPES
(pH 7.4 with NaOH). The pipette solution contained (in mM) 130 KCl,
1 MgCl2, 5 EGTA, 5 MgATP, and 10 HEPES (pH 7.2 with KOH). hERG
channel current was activated by depolarizing steps between − 70
and 50 mV from a holding potential of −80 mV. Tail current was recorded following repolarization to − 50 mV. All patch-clamp experiments
were performed at 22–23 °C.
2.6. Statistical analysis
Data are presented as mean ± standard error of mean. Student's
t-test was used for comparison between two groups. ANOVA with
Bonferroni correction was used for comparisons between more than
two groups. P b 0.05 is considered statistically signiﬁcant.
3. Results
3.1. LQT2 mutation R1032Gfs*25 but not D1037Rfs*82 leads to NMD
To determine the role of PTC position of LQT2 mutations in susceptibility to NMD, we studied two frameshift LQT2 mutations, R1032Gfs*25
and D1037Rfs*82. The R1032Gfs*25 and D1037Rfs*82 mutations have
been previously reported as G1301fs/24 (del3094) and G1036fs/82
(insG3107-3108), respectively (Splawski et al., 2000). We used a
minigene containing the hERG genomic sequence spanning exon 12 to
exon 15 (Fig. 1A) (Gong et al., 2007). R1032Gfs*25 introduces a PTC in
exon 14, and D1037Rfs*82 results in a PTC in the last exon (exon 15)
of the hERG gene. We stably expressed the WT and LQT2 mutant

Fig. 1. Analysis of the R1032Gfs*25 and D1037Rfs*82 mutations using minigene constructs. (A) Diagram of minigenes showing the positions of WT termination codon (TER) and mutationinduced PTCs. (B) RPA analysis of WT, R1032Gfs*25 and D1037Rfs*82 stably expressed in HEK293 cells. Cells were treated (+) or not treated (−) with 100 μg/ml of CHX for 3 h before RNA
isolation. The quantitative data after normalization using the level of hygromycin resistance gene (Hygro) are plotted as percentage of WT control (n = 4, ***P b 0.001, **P b 0.01).

minigenes in Flp-In HEK293 cells and performed RPA analysis. As shown
in Fig. 1B, R1032Gfs*25, but not D1037Rfs*82, led to a reduced level of
mutant mRNA compared to the WT minigene. Since NMD requires protein translation, cycloheximide (CHX) is often used to abrogate NMD.
Treatment with CHX had no effect on the levels of WT and D1037Rfs*82
mutant mRNA, but signiﬁcantly increased the level of R1032Gfs*25
mutant mRNA. These results suggest that position of PTC is important
for susceptibility of hERG mutations to NMD.
To further test the role of NMD in the reduction of R1032Gfs*25
mutant mRNA, we used RNA interference method to knock down
UPF1, a key NMD factor. In these experiments, we stably expressed
the hERG minigene and UPF1 shRNA in Flp–Cre HEK293 cells. Flp–Cre
cells contain a single copy of the FRT site and of the loxP2272/loxP
site, allowing expression of two genes of interest following Flp
recombinase-mediated recombination and Cre recombinase-mediated
cassette exchange reactions (Stump et al., 2012a). Knockdown of UPF1
protein was conﬁrmed by immunoblot using anti-UPF1 antibody
(Fig. 2A). RPA analysis showed that the level of the mutant hERG mRNA
was signiﬁcantly increased in the UPF1 shRNA-transfected cells compared
to that observed in scrambled shRNA-transfected cells (Fig. 2B).
These results indicated that NMD is responsible for the degradation
of R1032Gfs*25 mutant mRNA.
3.2. Downstream intron is required for NMD of R1032Gfs*25
Because the R1032Gfs*25 PTC is found in exon 14 and the
D1037Rfs*82 PTC occurs in exon 15, one explanation for the difference
in NMD sensitivity of these two mutations is the presence of downstream intron as proposed in the EJC-dependent model. To test whether
a downstream intron is required for NMD of R1032Gfs*25, we removed
intron 14 from the R1032Gfs*25 minigene construct (Fig. 3A). As shown
in Fig. 3B, the removal of intron 14 resulted in the restoration of
R1032Gfs*25 mutant mRNA and the treatment with CHX had no effect
on the level of mutant mRNA, suggesting that a downstream intron is
required for NMD of hERG PTC mutations.
3.3. PTC position and susceptibility to NMD
To determine the positional requirement of NMD of hERG mutations, we introduced PTC mutations into the hERG minigene at different
distances from the 3′-most exon–exon junction. Three PTC mutations

Fig. 2. Effect of suppression of UPF1 by RNA interference on NMD of R1032Gfs*25. A double stable mammalian expression system was used to express hERG minigenes and either
scrambled (Con) or UPF1 (UPF1) shRNAs. (A) Immunoblot analysis of UPF1 protein. (B)
RPA analysis of the effect of UPF1 knockdown. RPA signals were quantiﬁed, normalized
to hygromycin resistance gene (Hygro), and shown as percentage of WT control (n = 3,
***P b 0.001).

Fig. 3. Effect of downstream intron on NMD of the R1032Gfs*25 mutation. (A) Diagram of the minigenes of WT, R1032Gfs*25 and R1032Gfs*25 without intron 14. (B) RPA analysis of
mRNA from WT, R1032Gfs*25 and R1032Gfs*25 without intron 14 minigenes. Cells were treated (+) or not treated (−) with 100 μg/ml of CHX for 3 h before RNA isolation. RPA signals
were quantiﬁed, normalized to hygromycin resistance gene (Hygro), and shown as percentage of WT control (n = 3 or 4, **P b 0.01).

were introduced at the positions of 54 nt (S1092), 60 nt (S1090) and 66
nt (P1088) upstream of the 3′-most exon–exon junction in the spliced
minigene (Fig. 4A). As shown in Fig. 4B, PTCs at 60 nt and 66 nt, but
not 54 nt upstream of the 3′-most exon–exon junction resulted in a reduced level of mutant mRNA compared to the WT minigene. Treatment
with CHX had no effect on the levels of WT and 54 nt mutant mRNA, but
signiﬁcantly increased the level of 60 nt and 66 nt mutant mRNA. These
results suggest that PTCs at 60 nt and 66 nt, but not 54 nt upstream of
the 3′-most exon–exon junction lead to the degradation of mutant
mRNA by NMD.
3.4. The Y1078* mutation caused NMD leading to a reduction in mutant
protein expression and hERG current
The above mutational studies indicate that the boundary that separates NMD-sensitive and NMD-resistant PTC mutations resides between
residues 1090 and 1092 within exon 14, which is between 54 and 60 nt
upstream of the 3′-most exon–exon junction. To further test the positional effect of LQT2-associated NMD we characterized the Y1078*
mutation which represents the nearest LQT2 PTC mutation upstream
of this boundary. Y1078* has been previously reported as A1077fs +
X (3234delC, Kapplinger et al., 2009). The mutation introduces a PTC
at residue 1078, 34 nt upstream of the boundary or 94 nt upstream of
the 3′-most exon–exon junction. In order to study the effect of NMD
at the mRNA as well as the protein and functional levels, we introduced
the Y1078* mutation into a full-length hERG splicing-competent construct that contained hERG cDNA from exon 1 to exon 10 and hERG genomic DNA from intron 10 to the poly(A) site (Fig. 5A) (Gong et al.,
2011; Zarraga et al., 2011). We stably transfected WT and Y1078* fulllength hERG constructs into Flp–In HEK293 cells and performed RPA
analysis. As shown in Fig. 5B, the mRNA level from Y1078* was signiﬁcantly lower than the WT construct. Treatment with protein synthesis
inhibitor CHX had no effect on the WT mRNA level, but signiﬁcantly increased the mRNA level of Y1078*, suggesting that the Y1078* mutant
mRNA was degraded by NMD.
To determine whether NMD of the Y1078* mutant mRNA would
cause a decrease in hERG channel protein and function, we performed
immunoblot (Fig. 5C) and patch clamp experiments (Figs. 5D, E). The

Fig. 4. Effect of PTC position on NMD of hERG stop codon mutations. (A) Diagram of the PTC
position relative to the 3′-most exon–exon junction in the minigene and the spliced mRNA.
(B) RPA analysis of mRNA from HEK293 cells stably expressing WT and mutant minigenes
containing PTC mutations 54 nt, 60 nt and 66 nt upstream to the 3′-most exon–exon junction. Cells were treated (+) or not treated (−) with 100 μg/ml of CHX for 3 h before RNA isolation. RPA signals were quantiﬁed, normalized to hygromycin resistance gene (Hygro), and
shown as percentage of WT control (n = 3 or 4, **P b 0.01, *P b 0.05).

Fig. 5. Analysis of the Y1078* mutation in the context of full-length splicing-competent hERG construct. (A) Diagram of the full-length splicing-competent hERG construct. (B) RPA analysis
of mRNA from cells expressing WT and Y1078* constructs. Cells were treated (+) or not treated (−) with 100 μg/ml of CHX for 3 h before RNA isolation. RPA signals were quantiﬁed,
normalized to hygromycin resistance gene (Hygro), and shown as percentage of WT control (n = 3, ***P b 0.001). (C) Immunoblot analysis of WT hERG and Y1078* channel proteins.
Cell lysates were subjected to SDS-PAGE and immunoblotted with an antibody against the N-terminus of the hERG channel. The level of protein bands was quantiﬁed, normalized to
HPH, and shown as percentage of WT control (n = 3). (D) Representative currents recorded from HEK293 cells stably expressing WT and Y1078*. (E) I–V plot of tail current density measured at −50 mV following test voltages from −70 to 50 mV for WT and Y1078*.

WT construct expressed two protein bands at 135 kDa and 155 kDa,
representing the core-glycosylated immature form and the complexglycosylated mature form of hERG channel protein, respectively
(Gong et al., 2011). The Y1078* mutant generated two protein
bands at 125 kDa and 145 kDa, reﬂecting the deletion of 82 amino
acids due to the PTC at position 1078. The level of the Y1078* mutant
protein was markedly decreased. In patch clamp experiments, Y1078*
caused a signiﬁcant decrease in hERG current. The maximum tail current densities for WT and Y1078* were 21.0 ± 1.8 pA/pF (n = 7)
and 1.9 ± 0.4 pA/pF (n = 11, P b 0.001), respectively.

3.5. Inhibition of downstream intron splicing by antisense MO rescues
functional expression of the Y1078* mutant channels
To determine whether the splicing of downstream intron is
important in NMD of Y1078*, we used an antisense MO approach.
MOs are nonionic DNA analogs that can form RNA-morpholino hybrids
and inhibit splicing by blocking the access of splicing factors to splice
sites. We used an antisense MO that targets the 5′-splice site of intron
14 to inhibit the splicing of intron 14 (Fig. 6A) (Gong et al., 2011).
In these experiments, HEK293 cells stably expressing WT and Y1078*

Fig. 6. Inhibition of intron 14 splicing by antisense MO prevents NMD of Y1078*. Cells stably expressing the WT and Y1078* full-length splicing-competent hERG construct were treated
with 5 μM invert (Con) or antisense MO for 48 h. (A) Diagram of the full-length splicing-competent hERG construct and the sequences of antisense MO. (B) RPA analysis of the effect of
antisense MO. RPA signals were quantiﬁed, normalized to hygromycin resistance gene (Hygro) and shown as percentage of WT control (n = 3, **P b 0.01, *P b 0.05). (C) Immunoblot
analysis of the effect of antisense MO. Cell lysates were subjected to SDS-PAGE and immunoblotted with anti-hERG and anti-HPH antibodies. The level of protein bands was quantiﬁed,
normalized to HPH, and shown as fold changes in the presence of antisense MO (n = 4). (D) Representative currents recorded from HEK293 cells stably expressing Y1078* following treatment with 5-μM invert (Control) or antisense MO (AMO) for 48 h. (E) I–V plot of hERG tail current density measured at −50 mV following test voltages from −70 to 50 mV for WT and
Y1078* in the presence of invert or antisense MO.

full-length hERG splicing-competent constructs were treated with 5 μM
antisense or invert MO for 48 h. As shown in Fig. 6B, treatment with antisense MO had no effect on the WT mRNA level, but resulted in a signiﬁcant increase in the level of the Y1078* mutant mRNA compared to the

invert MO. These results suggest that inhibition of intron 14 splicing by
antisense MO can prevent NMD of the Y1078* mutant mRNA.
To demonstrate that inhibition of NMD by antisense MO also results
in rescue of Y1078* at protein level, we analyzed hERG protein expression

by immunoblot (Fig. 6C). Treatment with antisense MO signiﬁcantly
increased the level of the Y1078* mutant protein compared with the invert MO. These results suggest that inhibition of NMD by antisense MO
restores the expression of the Y1078* mutant protein. To study functional
rescue of Y1078*, we performed patch clamp recordings (Figs. 6D, E).
hERG current was signiﬁcantly increased by the antisense MO treatment
as compared to that observed in invert MO treated cells. The maximum
tail current densities for Y1078* treated with invert and antisense
MO were 2.2 ± 0.4 pA/pF (n = 10) and 17.2 ± 1.6 pA/pF (n = 11,
P b 0.001), respectively. These patch clamp results demonstrate that
inhibition of NMD by antisense MO can rescue functional expression
of the Y1078* mutation.
4. Discussion
Our present study deﬁnes the positional requirements for susceptibility of LQT2 mutations to NMD. Several lines of evidence were found
to support an EJC-dependent model for recognition of NMD substrates
in hERG PTC mutations. First, NMD occurs in LQT2 mutations that introduce a PTC in the penultimate exon, but not in the last exon. Second, a
downstream intron is required for NMD of the R1032Gfs*25 mutation.
Third, degradation of PTC-containing mRNA by NMD requires the presence of PTCs located N54–60 nt upstream of the 3′-most exon–exon
junction. Fourth, blocking of downstream intron splicing inhibits NMD
of the Y1078* mutation. The fact that blocking downstream intron splicing abrogates NMD of Y1078* strongly suggests that the physical distance between the termination codon and the poly(A)-binding protein
C1, as proposed by the EJC-independent model, is a not a crucial determinant for NMD of LQT2 mutations. We also show that suppression of
NMD by antisense MO leads to the rescue of Y1078* channel expression
and hERG current. These ﬁndings suggest that EJC-dependent NMD can
be prevented by targeting downstream intron splicing using antisense
MO, resulting in the rescue of functional expression of mutant proteins.
As N 30% of reported LQT2 mutations are nonsense and frameshift
mutations, identiﬁcation of the positional requirements for NMD in
hERG is of signiﬁcant importance in predicting pathogenic mechanism
based on the PTC location. Our results suggest that the 3′-boundary
for NMD of hERG PTC-containing mRNA is between residues S1090
and P1092 in exon 14. Among the LQT2 PTC mutations identiﬁed so
far, Y1078* is the nearest PTC mutation upstream of this boundary and
D1037Rfs*82 is the nearest PTC mutation downstream of this boundary.
We show that Y1078*, but not D1037Rfs*82 is sensitive to NMD. Thus,
LQT2 mutations that introduce PTC upstream of this 3′-boundary are
potential targets of NMD, while those harboring a PTC downstream of
this boundary are expected to escape NMD.
Our recent studies have indicated that LQT2 nonsense mutations
near the translational start site of hERG can escape NMD due to translation reinitiation at in-frame, downstream methionine codons (Stump
et al., 2012b, 2013). Translation of hERG transcripts containing the
C39* or C44* nonsense mutations is reinitiated at Met60 and resulted
in the generation of N-terminally truncated, trafﬁcking defective channels. hERG transcripts containing the Q81* mutation were translated
from Met124 and resulted in the expression of truncated, channels
with accelerated deactivation kinetics. Although the hERG gene contains many in frame methionine residues, only those with a strong
Kozak sequence near 5′-region of the transcript may be used for translation reinitiation (Kozak, 2001). We have shown that Met60, Met124,

Met133 and Met137 are capable of reinitiating translation (Stump
et al., 2012b, 2013). Translation reinitiation is compatible with an EJCdependent model of NMD in which the EJC-complexes are displaced
by the ribosome before they can associate with NMD machinery. The
LQT2 frameshift mutation A142Gfs*3, which is located downstream of
these methionine residues, fails to reinitiate translation and is sensitive
to NMD (Stump et al., 2012b). Thus, the 5′-boundary for NMD of hERG
PTC-containing mRNA is likely at M137. Transcripts containing PTC
upstream of this 5′-boundary may be translated into N-terminally truncated hERG channels, while those occurring downstream are predicted
to be degraded by NMD. In support of the proposed 5′- and 3′-boundaries governing NMD susceptibility, LQT2 PTC mutations located within
exons 3, 6, 8, 12, and 13 have previously been shown to be sensitive to
NMD (Gao et al., 2013; Gong et al., 2007; Stump et al., 2012b; Sun et al.,
2009; Zarraga et al., 2011). A review of the literature revealed that 161
out of 196 reported LQT2 nonsense and frameshift mutations are predicted to be degraded by NMD (Fig. 7, Supplemental Table S1).
In this study, we used the full-length splicing-competent hERG construct to characterize NMD at mRNA, protein and functional levels. We
showed that the Y1078* mutant mRNA was degraded leading to a
marked decrease in the expression of hERG channel protein and a nearly
complete loss of hERG current. Our present work highlights the importance of using splicing-competent hERG constructs in the characterization of LQT2 PTC mutations. To date, several LQT2 nonsense and
frameshift mutations have been analyzed using cDNA constructs
under the assumption that PTC mutations would generate truncated
hERG channels (Choe et al., 2006; Christé et al., 2008; Gong et al.,
2004; Li et al., 1997; Nof et al., 2010; Paulussen et al., 2005; Trudeau
et al., 2011). However, based on the 3′-boundary identiﬁed in the
present study, all of these PTC mutations are expected targets of NMD.
Because NMD of hERG PTC-bearing mRNA requires splicing of a downstream intron, the effect of NMD is not observed in the context of
cDNA constructs. It is noted that most of these nonsense and frameshift
mutations exhibit a dominant-negative effect on WT hERG channels in
these cDNA-based studies (Choe et al., 2006; Christé et al., 2008; Gong
et al., 2004; Li et al., 1997; Nof et al., 2010; Paulussen et al., 2005;
Trudeau et al., 2011). However, if these studies were performed using
an NMD-competent construct, the PTC-containing mRNA would be degraded and the dominant-negative effect caused by truncated proteins
would be minimized.
In conclusion, our results identify the positional requirements that
determine the susceptibility of hERG PTC mutations to NMD. Our data
strongly support an EJC-dependent mechanism of NMD and indicate
that the majority of reported LQT2 nonsense and frameshift mutations
are potential targets of NMD.
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Fig. 7. Schematic of hERG mRNA (exons 1–15) and the 5′ and 3′ boundaries that govern the susceptibility of LQT2 frameshift and nonsense mutations to NMD. The relative position and
number of NMD-resistant and NMD-sensitive LQT2 PTC mutations are shown.

Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gene.2014.02.012.
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